Renee P. Tannenbaum Sells 2,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Free Report) Director Renee P. Tannenbaum sold 2,000 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $63.87, for a total value of $127,740.00. Following the completion of the sale, the director now owns 18,211 shares in the company, valued at $1,163,136.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

ANI Pharmaceuticals Stock Down 3.7 %

Shares of NASDAQ ANIP opened at $61.43 on Friday. ANI Pharmaceuticals, Inc. has a 52 week low of $44.06 and a 52 week high of $70.81. The company has a market cap of $1.29 billion, a P/E ratio of 38.39 and a beta of 0.80. The company has a quick ratio of 3.12, a current ratio of 3.95 and a debt-to-equity ratio of 0.63. The business has a 50-day simple moving average of $66.78 and a two-hundred day simple moving average of $59.65.

ANI Pharmaceuticals (NASDAQ:ANIPGet Free Report) last issued its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ANIP. Texas Permanent School Fund Corp raised its position in shares of ANI Pharmaceuticals by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock worth $912,000 after buying an additional 172 shares in the last quarter. New York State Teachers Retirement System increased its stake in ANI Pharmaceuticals by 0.9% in the 3rd quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after acquiring an additional 200 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of ANI Pharmaceuticals by 1.5% in the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 233 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of ANI Pharmaceuticals by 9.2% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 4,754 shares of the specialty pharmaceutical company’s stock valued at $276,000 after acquiring an additional 400 shares during the last quarter. Finally, ProShare Advisors LLC grew its holdings in shares of ANI Pharmaceuticals by 10.0% during the first quarter. ProShare Advisors LLC now owns 4,447 shares of the specialty pharmaceutical company’s stock worth $307,000 after purchasing an additional 404 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on ANIP. Capital One Financial began coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They set an “overweight” rating and a $80.00 price target for the company. HC Wainwright boosted their price target on shares of ANI Pharmaceuticals from $83.00 to $87.00 and gave the company a “buy” rating in a research report on Monday, May 13th. Guggenheim reaffirmed a “buy” rating and issued a $77.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Finally, Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Buy” and an average target price of $81.00.

Get Our Latest Analysis on ANI Pharmaceuticals

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Featured Articles

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.